Novel anticancer activity of phloroglucinol against breast cancer stem-like cells.
Toxicol Appl Pharmacol
; 286(3): 143-50, 2015 Aug 01.
Article
em En
| MEDLINE
| ID: mdl-25843036
ABSTRACT
Poor prognosis of breast cancer patients is closely associated with metastasis and relapse. There is substantial evidence supporting that cancer stem-like cells (CSCs) are primarily responsible for relapse in breast cancer after anticancer treatment. However, there is a lack of suitable drugs that target breast cancer stem-like cells (BCSCs). Here, we report that phloroglucinol (PG), a natural phlorotannin component of brown algae, suppresses sphere formation, anchorage-independent colony formation and in vivo tumorigenicity. In line with these observations, treatment with PG also decreased CD44(+) cancer cell population as well as expression of CSC regulators such as Sox2, CD44, Oct4, Notch2 and ß-catenin. Also, treatment with PG sensitized breast cancer cells to anticancer drugs such as cisplatin, etoposide, and taxol as well as to ionizing radiation. Importantly, PG inhibited KRAS and its downstream PI3K/AKT and RAF-1/ERK signaling pathways that regulate the maintenance of CSCs. Taken together, our findings implicate PG as a good candidate to target BCSCs and to prevent the disease relapse.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Floroglucinol
/
Células-Tronco Neoplásicas
/
Neoplasias da Mama
/
Antineoplásicos
Tipo de estudo:
Prognostic_studies
Limite:
Animals
/
Female
/
Humans
Idioma:
En
Revista:
Toxicol Appl Pharmacol
Ano de publicação:
2015
Tipo de documento:
Article